GenAI-Augmented Data Analytics in Screening and Monitoring of Cervical and Breast Cancer: A Novel Approach to Precision Oncology

Marcus Rodriguez[1*], Kawsher Rahman[2], Krishna Devarapu[3], Narayana Reddy Bommu Sridharlakshmi[4], Pavan Kumar Gade[5], Abhishekar Reddy Allam[6]

[1]Princeton Institute for Computational Science and Engineering (PICSciE), Princeton University, NJ, USA
[2]In-Charge and RMO, Beanibazar Cancer and General Hospital, Sylhet, Bangladesh
[3]Senior Data Solutions Architect, Mission Cloud Services Inc., Beverley Hills, CA, USA
[4]SAP Master Data Consultant, Data Solutions Inc., 28345 Beck Road, Suite 406, Wixom, MI 48393, USA
[5,6]Software Developer, City National Bank, Los Angeles, CA, USA

[*]Corresponding Contact:
Email: marcusrodriguez640@gmail.com

ABSTRACT

This research examines how Generative Artificial Intelligence (GenAI) might improve cervical and breast cancer screening and monitoring data analytics to improve diagnosis accuracy and patient care in precision oncology. We evaluate literature and secondary data to show how GenAI technologies, including improved imaging analysis, genetic data integration, and predictive modeling, might improve early diagnosis and patient care. Significant results show that GenAI improves imaging analysis and genetic insights to personalize treatment approaches, enhancing diagnostic efficiency. However, model interpretability, data bias, and resource restrictions prevented broad deployment. The paper underlines the need for legislative frameworks that support explainable AI, safe data-sharing protocols, and inclusive datasets to guarantee different groups have fair access to GenAI applications. These issues must be addressed for GenAI to enhance cancer treatment, improve patient outcomes, and create a more equitable healthcare system. This study adds to the discussion on AI and oncology and highlights GenAI's potential to enhance precision cancer treatment.

Key words:
Generative Artificial Intelligence (GenAI), Precision Oncology, Breast Cancer, Cervical Cancer, Data Analytics, Cancer Screening, Predictive Modeling

5/15/2023 **Source of Support:** None, **No Conflict of Interest:** Declared

INTRODUCTION

Cancer kills most people globally, with breast and cervical cancers being the most common among women. Breast cancer is the most common cancer in women and causes significant worldwide mortality. In low- and middle-income countries (LMICs), when screening and early detection programs are few, cervical cancer is an important health issue. Despite therapy advances, breast and cervical cancer patients' prognoses depend on early identification and management. Precision oncology, which tailors therapies to each patient's genetic, environmental, and lifestyle characteristics, has emerged as a promising approach to enhancing patient outcomes. Traditional cancer screening and monitoring data analytics struggle to analyze and comprehend the massive volumes of complex, multimodal data needed for precision treatment. Generative Artificial Intelligence (GenAI) may improve data-driven cancer diagnosis and management to solve these problems (Ahmmed et al., 2021; Thompson et al., 2019; Venkata et al., 2022).

GenAI in data analytics might improve cancer analysis, prediction, and monitoring, transforming precision oncology (Allam, 2020). GenAI models like big language models and generative adversarial networks (GANs) may generate synthetic data, evaluate medical pictures, and improve medical natural language processing (Boinapalli, 2020; Thompson et al., 2022). GenAI can synthesize complicated patient data—from genetic profiles to imaging findings and clinical notes—to improve cancer identification and surveillance in oncology. GenAI-augmented data analytics can accurately identify high-risk breast and cervical cancer patients, forecast disease progression and track therapy responses (Deming et al., 2021; Sridharlakshmi, 2021). This technique may help reduce cancer treatment inequalities in impoverished areas with few diagnostic resources. Data privacy issues limit GenAI's promise in cancer screening and monitoring, the requirement for explainable AI models, and the necessity to integrate sophisticated analytics into healthcare processes (Devarapu et al., 2019; Gade et al., 2021; Sridharlakshmi, 2020). Healthcare data is sensitive and requires strong security and privacy protections, especially in locations with diverse governmental control. Clinical GenAI adoption needs interpretable and accurate models for healthcare practitioners to make educated judgments. These technologies must also be accessible and useable in varied healthcare settings, especially resource-limited ones.

This research introduces GenAI-augmented data analytics for breast and cervical cancer screening and monitoring in precision oncology. We discuss existing cancer screening and monitoring methods and how GenAI might improve prediction accuracy, customization, and efficiency. We hope to show how GenAI may improve precision oncology for breast and cervical cancer patients via practical applications, obstacles, and prospects. GenAI's ability to analyze complicated information may help healthcare practitioners improve patient outcomes across clinical settings by making treatments more accurate and timely. This strategy promotes precision oncology and might democratize global cancer treatment.

STATEMENT OF THE PROBLEM

Cervical and breast cancers remain the primary causes of morbidity and death in women in high-income and low- and middle-income nations despite advances in detection and therapies. Effective cancer care requires screening and monitoring for early identification, prompt intervention, and better patient outcomes. However, current cancer screening approaches generally lack the accuracy, sensitivity, and flexibility to suit patients' unique demands. Oncology's traditional data analytics frameworks fail to manage the complexity and amount of data needed for proper diagnosis and monitoring. These frameworks may miss small trends in multimodal data like genetics, medical imaging, and patient histories, resulting in delayed diagnosis, misdiagnosis, and inappropriate therapy. Precision oncology, which tailors treatment to each cancer patient, relies on overcoming these limits to give more tailored, effective care.

GenAI is transforming healthcare, especially data analytics. GenAI can improve diagnosis accuracy and effectiveness by processing massive volumes of organized and unstructured data (Gade et al., 2022; Rodriguez et al., 2020). GenAI models like generative adversarial networks (GANs) and large language models excel at synthesizing complex information, generating synthetic data, and interpreting natural language, which is essential for oncology applications that use patient data from many sources (Gummadi et al., 2020; Rodriguez et al., 2019). GenAI is underutilized in breast and cervical cancer screening and monitoring despite its promise. GenAI-augmented data analytics' integration with clinical processes, diagnosis accuracy, and patient outcomes in real-world healthcare settings must be better studied.

This work investigates GenAI-augmented data analytics for cervical and breast cancer screening and monitoring to fill these gaps. The research examines how GenAI might improve cancer data analytics by identifying high-risk patients, forecasting disease progression, and tracking therapy responses. This study investigates if GenAI can help precision oncology patients get better, more personalized cancer treatment. This work examines GenAI models in this setting to improve diagnostic sensitivity and accuracy, providing doctors with enhanced decision-making tools that improve patient outcomes.

This work offers a realistic solution to integrate sophisticated AI-driven analytics into regular cancer screening and surveillance, advancing precision oncology. The enormous worldwide incidence of breast and cervical cancer, particularly in underprivileged places, makes this study important for democratizing high-quality cancer diagnostics. This research lays the groundwork for GenAI integration in additional cancer care domains by connecting theoretical GenAI applications to patient-centered outcomes in oncology. This study emphasizes ethical and transparent GenAI application, setting norms for data protection, model interpretability, and fair clinical access. This study advances the scientific knowledge of GenAI's function in oncology and answers clinical requirements in cancer prevention and therapy, providing the framework for a more precise and accessible cancer care future.

METHODOLOGY OF THE STUDY

This secondary data-based analysis examines how GenAI enhances data analytics for cervical and breast cancer screening and monitoring. This literature review addresses GenAI applications, difficulties, and potential in precision oncology. The sources include peer-reviewed scientific publications, systematic reviews, clinical trial reports, and relevant case studies using GenAI models like GANs and NLP tools in cancer data analytics. PubMed, IEEE Xplore, and Google Scholar were searched for recent and essential studies, emphasizing research published within the previous decade for relevance to contemporary technology. The research seeks to understand GenAI's potential to improve data-driven cancer diagnosis and monitoring procedures' accuracy, sensitivity, and flexibility via this thorough evaluation.

ADVANCEMENTS IN GENAI FOR ONCOLOGY DATA ANALYTICS

GenAI has advanced data analytics in oncology, improving cancer screening and monitoring accuracy and effectiveness. GenAI includes sophisticated models like GANs, transformer-based language models, and variational autoencoders that analyze complicated, multidimensional data (Gummadi et al., 2021; Kundavaram et al., 2018). These models can generate synthetic data, evaluate medical imaging, and analyze unstructured clinical literature, making them ideal for oncology difficulties with many data sources.

GenAI's integration with oncology data analytics will benefit Precision oncology, enhancing diagnosis, therapy, and disease progression monitoring for high-prevalence malignancies, including cervical and breast cancer (Zhang et al., 2017).



Figure 1: Advancements in GenAI in Oncology

The developments in the three main fields of oncology-related Generative Artificial Intelligence (GenAI) are shown in the triple bar graph in Figure 1. Precision of diagnosis, individualization of therapy, and patient tracking.

A major GenAI innovation in oncology is medical imaging, crucial to cancer detection and monitoring. Traditional tumor detection and assessment by radiologists and oncologists uses MRI, CT, and mammography. Interpreting these pictures is complicated and prone to human mistakes. By creating synthetic photos that mimic tumor features or enhancing existing images to show hidden patterns, GANs, and other GenAI algorithms may eliminate these discrepancies. GANs may reduce noise and improve resolution in low-resource environments, allowing doctors to evaluate more accurately with less modern imaging equipment. GenAI models can also recognize tumor size, shape, and texture, helping radiologists discover and analyze breast and cervical malignancies early (Lubelski et al., 2018).

The NLP branch of GenAI has improved the analysis of unstructured clinical data, including EHRs, pathology reports, and physician notes. NLP models, huge language models, may extract meaningful information from these sources, which frequently reveal a patient's disease history, treatment plans, and response to medicines. GenAI improves patient monitoring and disease progression by quantifying qualitative data. NLP may identify patterns from longitudinal patient data to monitor symptoms, side effects, and other markers for individualized cervical and breast cancer therapy.

GenAI in genomic analysis is another cancer data analytics milestone. Genomic data reveals cancer's start and progression mutations and biomarkers. GenAI can find patterns and connections in large genomic datasets that standard approaches cannot. This is especially useful in breast and cervical cancers, where genetic variables affect susceptibility, treatment response, and recurrence. GenAI models may combine genetic profiles with imaging and clinical information to provide more accurate cancer risk estimates (Lorgelly et al., 2016).

The combination of GenAI-driven data analytics advances might change precision oncology. GenAI can greatly enhance screening and diagnosis for breast and cervical cancer, where early identification and monitoring are crucial. Using varied data sources, GenAI can do more complex risk assessments and individualized monitoring, ensuring patients get prompt and focused treatment. GenAI's capacity to produce high-quality synthetic data may help overcome data scarcity, especially in low-resource situations without extensive datasets. This may make high-quality diagnostics accessible and help create more inclusive, fair cancer care systems.

The latest GenAI for oncology data analytics advances may solve some of the most extensive cancer screening and monitoring problems. GenAI increases precision oncology by improving image analysis, genetic insights, and data-driven monitoring, allowing more tailored, efficient, and accessible breast and cervical cancer treatment globally.

GENAI APPLICATIONS IN CANCER SCREENING AND MONITORING

GenAI is improving cancer screening and monitoring by making disease detection and management more accurate, efficient, and accessible, especially in breast and cervical cancer. Due to cancer's complexity and unpredictability, imaging and genetic profiles, clinical notes, and patient histories are needed to diagnose it. GenAI's capacity to synthesize, evaluate, and supplement this data gives oncology a new degree of customization and precision. GenAI's cervical and breast cancer screening and monitoring uses are listed below (Meng et al., 2019).

Table 1: Comparison of AI Techniques

AI Technique	Description	Use in Cancer Screening	Examples
Deep Learning	Neural networks with multiple layers for data analysis.	Image analysis for tumor detection.	Convolutional Neural Networks (CNNs).
Natural Language Processing	AI analyzing and understanding human language.	Analyzing patient records and feedback.	Chatbots and patient interaction tools.
Reinforcement Learning	AI learns optimal actions through trial and error.	Personalized treatment plans.	Adaptive therapy systems.
Generative Adversarial Networks (GANs)	AI generates synthetic data for model training.	Enhancing datasets for rare cancers.	Creating realistic images for training models.

Table 1 contrasts many AI methods for cancer screening, emphasizing their descriptions, particular uses in the industry, and real-world instances. This comparison may help us better understand the advantages and uses of various AI approaches.

Better Imaging Analysis and Diagnosis

Cancer screening relies on medical imaging, including mammography, MRI, and ultrasound for breast cancer. Traditional imaging interpretation takes time, and radiologists vary. GenAI improves picture quality, identifies subtle patterns, and automates diagnostic procedures using GANs and CNNs (Fan et al., 2019). GANs may produce synthetic tumor pictures for diagnostic model training in data-scarce locations (Karanam et al., 2018). They also improve imaging data resolution, making early-stage tumor diagnosis more accurate in low-quality images. In cervical cancer screening, GenAI models can detect minute cellular changes that the human eye cannot, identifying pre-cancerous tumors more accurately. This eliminates diagnostic mistakes and speeds screening, helping radiologists make better judgments quicker.

Genomic Data Integration for Precision Screening

Genomic data analysis is essential for screening and monitoring breast and cervical cancers due to genetic risk factors. Cancer research's massive and complicated genetic databases are ideal for GenAI. GenAI uses transformer-based designs to discover genetic mutations, biomarkers, and inherited risk factors for cancer, providing insights into each patient's cancer risk profile. GenAI can evaluate genomic profiles in breast cancer to predict tumor susceptibility, uncover actionable mutations, and identify individuals who may benefit from genetically tailored treatments. This strategy promotes precision oncology, which tailors therapy and monitoring to each cancer case's genomic features. GenAI can also detect high-risk cervical cancer patients by studying HPV genome patterns and genetic predispositions, enabling early intervention and enhancing screening accuracy (Marton, 2012).

Clinical Data Extraction using NLP

Cancer patients' data is commonly maintained in unstructured forms, including EHRs, pathology reports, and clinical notes. Monitoring cancer development requires actionable insights from this information, but manual examination is resource-intensive. GenAI models that use NLP, such as big language models, extract meaningful information from these sources accurately and automatically. NLP may analyze EHRs to identify symptom patterns, monitor therapy responses, and identify high-risk patients for further assessment. NLP technologies may enhance tailored cervical and breast cancer therapy by continually evaluating patient data for recurrence or treatment side effects. GenAI-powered NLP tools let oncologists make data-driven choices and follow patient outcomes in real-time by turning unstructured clinical data into quantitative measurements, enhancing treatment.

Disease Progression and Treatment Response Prediction

GenAI's predictive modeling of disease progression and treatment results using patient data is a game-changer in cancer care. By examining historical and present data, GenAI models can forecast how a breast or cervical cancer case will evolve and how a patient will react to therapy. Using this predictive capability, oncologists may optimize treatment programs and monitor schedules for each patient. GenAI models may predict cancer recurrence or metastasis using previous tumor growth trends, patient demographics, and treatment responses. Breast cancer prediction models may help determine hormone therapy, chemotherapy, and radiation effectiveness, allowing for prompt treatment modifications. GenAI techniques can anticipate chemoradiation responses in cervical cancer, allowing physicians to schedule follow-up examinations and supportive care based on each patient's expected treatment trajectory (Golembiewski et al., 2019).

Synthetic Data Generation for Research and Training

Another critical GenAI application is the generation of synthetic cancer patient data. This generated data may help train diagnostic algorithms when high-quality data is unavailable owing to privacy or geographical issues. GenAI creates realistic, de-identified data to build strong, generalizable models without compromising patient privacy. Breast and cervical cancer research benefits from synthetic data production because unusual cases or tumor subtypes may not be well-represented in current databases. Training models on synthetic data helps researchers and clinicians enhance diagnostic tools, comprehend heterogeneous cancer presentations, and increase model performance in various clinical circumstances.

CHALLENGES AND FUTURE DIRECTIONS IN PRECISION ONCOLOGY

GenAI offers excellent potential in precision oncology, especially for breast and cervical cancer screening and monitoring. Implementing these sophisticated technologies presents various problems that must be overcome to maximize their potential. Technical, operational, ethical, and resource issues are among these concerns. These difficulties must be addressed to maintain GenAI-augmented precision oncology, where sophisticated data analytics may become standard cancer treatment. This chapter describes the main obstacles to using GenAI for cancer screening and monitoring and suggests solutions.



Figure 2: Funding Allocation in Precision Oncology

The Figure 2 pie chart shows precision oncology funding by sector. Research is the most significant sector, at 40%, indicating its significance in knowledge and cures. Clinic trials follow with 30%, showing a substantial investment in novel therapy efficacy. Technology development, essential for innovation and execution, receives 20% of the investment. Finally, patient access projects receive 10% to emphasize the need to make precision oncology advances available to patients.

Data Security and Privacy Issues: GenAI in oncology has significant data privacy and security issues. Cancer screening and monitoring need sensitive patient data such as genetic data, medical pictures, and clinical records. GenAI can synthesize and interpret data. However, patient confidentiality and data exploitation are problems. Privacy laws like the EU's General Data Protection Regulation (GDPR) and the U.S.'s

HIPAA restrict healthcare data storage, sharing, and processing. GenAI models that comply with these requirements need robust data anonymization, access restrictions, and safe data storage. Due to the high stakes of oncology data, encryption and blockchain-based solutions that monitor and authenticate data access are needed to ensure openness and accountability (Shafqat et al., 2018).

GenAI Model Interpretability and Trustworthiness: The intricacy of GenAI models, intense learning, and neural network structures make interpretation difficult. Clinicians need reliable, interpretable models for life-critical cancer treatment choices. Healthcare practitioners may distrust black-box models that deliver outcomes without a justification, limiting GenAI usage in clinical settings (Kommineni et al., 2020). GenAI models must be visible, interpretable, and dependable to gain physician confidence. Develop explainable AI (XAI) approaches, including visualization tools and attention processes to explain model findings.

Generalizability across diverse populations: GenAI model accuracy across varied populations is a precision oncology problem. Cancer frequency, genetics, and healthcare access vary by geography and population. However, many GenAI models have been trained on datasets that only reflect some populations, which may skew diagnostic and predictive performance. An AI model trained on high-resource data may translate poorly to low-resource situations, as imaging equipment quality and clinical procedures vary. We need more varied, inclusive datasets with various demographic factors to fix this. GenAI-enabled synthetic data creation may increase underrepresented instances and model robustness across clinical settings (Covvey et al., 2019).

Resource and Infrastructure Constraints: GenAI solutions in cancer demand computing resources and technical skills that may not be accessible in all healthcare settings. High-income nations may have the infrastructure and finances to adopt GenAI, while LMICs generally lack these resources, restricting access to sophisticated cancer screening and monitoring technologies. GenAI model maintenance and updates may be expensive, especially for smaller healthcare organizations (Kothapalli et al., 2019). Future efforts should produce cost-effective, resource-efficient GenAI models with reduced computing needs. Cloud-based solutions and federated learning, where models are trained on decentralized data across several institutions, may help close resource gaps and distribute GenAI-enhanced cancer treatment more evenly.

Ethics and Regulation: Healthcare using GenAI presents ethical problems concerning autonomy, consent, and justice. Patients may be involved if their data is shared between institutions or used to train models for other groups. Addressing these issues requires transparent communication and informed consent. However, healthcare AI regulations are continually changing. GenAI models need continual model upgrades based on fresh data, which current medical device and software standards cannot handle.

Future Directions: The future of GenAI in precision oncology depends on technical innovation, ethical frameworks, and regulatory change. Developing interpretable, secure, and generalizable models is crucial for clinical adoption. Academic, industrial, and healthcare stakeholders may collaborate to produce inclusive datasets and exchange best practices for fair AI development. Regulatory frameworks must adapt to healthcare for GenAI breakthroughs to provide safe, and effective cancer treatment (Zarakovitis et al., 2018).

GenAI may improve cancer screening and monitoring, but these problems must be addressed to utilize its precision oncology potential fully. GenAI can improve cancer treatment by providing individualized, high-quality diagnoses and monitoring to patients across varied demographics and healthcare settings via collaborative, inclusive, and ethical initiatives.

MAJOR FINDINGS

Using Generative Artificial Intelligence (GenAI) to enhance data analytics for cervical and breast cancer screening and monitoring has yielded numerous notable results that might progress precision oncology. GenAI addresses persistent cancer care issues by synthesizing multiple data sources, improving diagnosis accuracy, and providing tailored patient monitoring. The main conclusions of this study on GenAI's cancer applications, advantages, and drawbacks are below.

GenAI-Powered Imaging Improves Diagnostic Accuracy and Efficiency: GenAI might improve cancer diagnosis accuracy and efficiency thanks to medical imaging advances. Generational adversarial networks (GANs) and convolutional neural networks (CNNs) enhance the quality of the picture, reduce noise, and generate synthetic training data. GenAI models have helped detect breast cancer tumors early by detecting small patterns in mammography and MRI data that doctors may overlook. GenAI can also identify pre-cancerous lesions in high-resolution cervical cancer imaging, improving diagnostic sensitivity and lowering human error. This enhances screening reliability and simplifies the process, allowing quicker and more precise decision-making.

Genomic and Clinical Data Personalize Cancer Screening and Monitoring: GenAI in genomic and clinical data analytics personalizes cancer therapy. GenAI models may discover breast and cervical cancer biomarkers, genetic mutations, and inherited risk factors by examining genomic profiles. This helps doctors identify high-risk individuals and adjust therapies with focused screening. GenAI can also evaluate longitudinal healthcare data for ongoing patient monitoring, including EHRs, pathology reports, and patient histories. GenAI extracts actionable data from unstructured clinical texts using NLP models to drive individualized therapy and follow-up strategies.

Predictive Modeling for Proactive Cancer Management: GenAI's prediction of cancer progression and treatment response is another significant result. GenAI models use historical data and patient-specific characteristics to predict illness progression and therapy response. This prognostic power is crucial in breast and cervical cancer, where early intervention might improve results. GenAI-driven prediction models let doctors alter treatment approaches depending on expected illness trajectories. This may maximize resource allocation, therapeutic effectiveness, and patient quality of life by minimizing unneeded or ineffective therapies.

Model Interpretability/Generalizability Issues: GenAI has transformational promise in cancer. However, model interpretability and generalizability could be improved. Complex GenAI models like deep neural networks make predictions hard for physicians to interpret, which may undermine faith in automated diagnosis. Concerns concerning bias and dependability arise because many GenAI models have been trained on datasets that may not reflect breast and cervical cancer patients' heterogeneous demographics. To make GenAI models relevant across demographic and geographic settings, explainable AI (XAI) approaches, and more inclusive, heterogeneous datasets must be improved.

Resource—and Ethical-Related Barriers: The research also found ethical and resource constraints to GenAI use in cancer. GenAI uses sensitive patient data, making data privacy a priority. GenAI models demand a lot of computing resources, which might be difficult for healthcare professionals in low—and middle-income nations. These results imply the need for safe, privacy-compliant data-sharing frameworks and resource-efficient GenAI models that can function in varied healthcare contexts to democratize advanced cancer treatment.

GenAI can enhance breast and cervical cancer screening and surveillance via image analysis, tailored data integration, and predictive modeling. To maximize GenAI's precision oncology potential, interpretability, generalizability, ethics, and resource restrictions must be addressed. These results demonstrate GenAI's revolutionary power and the strategic steps to integrate it into cancer treatment.

LIMITATIONS AND POLICY IMPLICATIONS

GenAI-augmented data analytics can revolutionize breast and cervical cancer screening and surveillance, but there are limits. First, GenAI models are difficult to comprehend because complicated algorithms need more transparency, reducing clinician faith in automated diagnosis. Training data biases may also limit these models, which may not reflect varied patient groups and contribute to inequitable treatment results. Low- and middle-income countries (LMICs) with limited healthcare resources have additional accessibility challenges due to high computational demands. Policy efforts could create explainability requirements in AI-driven diagnostics and invest in resource-efficient, inclusive GenAI models to overcome these difficulties. Privacy legislation must also change to allow safe, cross-border data exchange to protect patient privacy and model accuracy. These policies are necessary to make GenAI's precision oncology advantages accessible, egalitarian, and ethical.

CONCLUSION

GenAI in data analytics for breast and cervical cancer screening and monitoring is a potential precision oncology improvement. GenAI uses advanced algorithms to improve imaging analysis, integrate genetic and clinical data, and control cancer via predictive modeling. These capabilities might enhance early diagnosis, treatment results, and long-term patient monitoring, advancing personalized cancer care. However, many obstacles remain. GenAI models' complexity, opacity, and training data biases restrict interpretability and generalizability, which may affect physician trust and patient outcomes. GenAI deployment requires a lot of resources, limiting access in low-resource environments. Equitable solutions are needed. Policy and technological development must include explainable AI, inclusive datasets, and privacy-compliant data-sharing frameworks to address these restrictions. Policy frameworks and regulatory requirements must change to enable ethical, transparent, and secure GenAI use in healthcare. GenAI might revolutionize precision oncology by providing diverse populations with high-quality, individualized cancer treatment with strategic innovation and governmental support. As GenAI matures, its use in cancer treatment might improve patient outcomes and make oncology more egalitarian globally.

REFERENCES

Ahmmed, S., Narsina, D., Addimulam, S., & Boinapalli, N. R. (2021). AI-Powered Financial Engineering: Optimizing Risk Management and Investment Strategies. Asian Accounting and Auditing Advancement, 12(1), 37–45. https://4ajournal.com/article/view/96

Allam, A. R. (2020). Integrating Convolutional Neural Networks and Reinforcement Learning for Robotics Autonomy. *NEXG AI Review of America, 1*(1), 101-118.

Boinapalli, N. R. (2020). Digital Transformation in U.S. Industries: AI as a Catalyst for Sustainable Growth. *NEXG AI Review of America, 1*(1), 70-84.

Covvey, J. R., Kamal, K. M., Gorse, E. E., Mehta, Z., Dhumal, T. (2019). Barriers and Facilitators to Shared Decision-making in Oncology: A Systematic Review of the Literature. *Supportive Care in Cancer*, *27*(5), 1613-1637. https://doi.org/10.1007/s00520-019-04675-7

Deming, C., Pasam, P., Allam, A. R., Mohammed, R., Venkata, S. G. N., & Kothapalli, K. R. V. (2021). Real-Time Scheduling for Energy Optimization: Smart Grid Integration with Renewable Energy. *Asia Pacific Journal of Energy and Environment*, *8*(2), 77-88. https://doi.org/10.18034/apjee.v8i2.762

Devarapu, K., Rahman, K., Kamisetty, A., & Narsina, D. (2019). MLOps-Driven Solutions for Real-Time Monitoring of Obesity and Its Impact on Heart Disease Risk: Enhancing Predictive Accuracy in Healthcare. *International Journal of Reciprocal Symmetry and Theoretical Physics*, *6*, 43-55. https://upright.pub/index.php/ijrstp/article/view/160

Fan, Y., Mu, J., Huang, M., Imani, S., Wang, Y. (2019). Epigenetic Identification of ADCY4 as a Biomarker for Breast Cancer: An Integrated Analysis of Adenylate Cyclases. *Epigenomics*, *11*(14), 1561–1579. https://doi.org/10.2217/epi-2019-0207

Gade, P. K., Sridharlakshmi, N. R. B., Allam, A. R., & Koehler, S. (2021). Machine Learning-Enhanced Beamforming with Smart Antennas in Wireless Networks. *ABC Journal of Advanced Research*, *10*(2), 207-220. https://doi.org/10.18034/abcjar.v10i2.770

Gade, P. K., Sridharlakshmi, N. R. B., Allam, A. R., Thompson, C. R., & Venkata, S. S. M. G. N. (2022). Blockchain's Influence on Asset Management and Investment Strategies. *Global Disclosure of Economics and Business*, *11*(2), 115-128. https://doi.org/10.18034/gdeb.v11i2.772

Golembiewski, E., Allen, K. S., Blackmon, A. M., Hinrichs, R. J., Vest, J. R. (2019). Combining Nonclinical Determinants of Health and Clinical Data for Research and Evaluation: Rapid Review. *JMIR Public Health and Surveillance*, *5*(4). https://doi.org/10.2196/12846

Gummadi, J. C. S., Narsina, D., Karanam, R. K., Kamisetty, A., Talla, R. R., & Rodriguez, M. (2020). Corporate Governance in the Age of Artificial Intelligence: Balancing Innovation with Ethical Responsibility. *Technology & Management Review*, *5*, 66-79. https://upright.pub/index.php/tmr/article/view/157

Gummadi, J. C. S., Thompson, C. R., Boinapalli, N. R., Talla, R. R., & Narsina, D. (2021). Robotics and Algorithmic Trading: A New Era in Stock Market Trend Analysis. *Global Disclosure of Economics and Business*, *10*(2), 129-140. https://doi.org/10.18034/gdeb.v10i2.769

Karanam, R. K., Natakam, V. M., Boinapalli, N. R., Sridharlakshmi, N. R. B., Allam, A. R., Gade, P. K., Venkata, S. G. N., Kommineni, H. P., & Manikyala, A. (2018). Neural Networks in Algorithmic Trading for Financial Markets. *Asian Accounting and Auditing Advancement, 9*(1), 115–126. https://4ajournal.com/article/view/95

Kommineni, H. P., Fadziso, T., Gade, P. K., Venkata, S. S. M. G. N., & Manikyala, A. (2020). Quantifying Cybersecurity Investment Returns Using Risk Management Indicators. Asian Accounting and Auditing Advancement, 11(1), 117–128. https://4ajournal.com/article/view/97

Kothapalli, S., Manikyala, A., Kommineni, H. P., Venkata, S. G. N., Gade, P. K., Allam, A. R., Sridharlakshmi, N. R. B., Boinapalli, N. R., Onteddu, A. R., & Kundavaram, R. R. (2019). Code Refactoring Strategies for DevOps: Improving Software Maintainability and Scalability. *ABC Research Alert*, *7*(3), 193–204. https://doi.org/10.18034/ra.v7i3.663

Kundavaram, R. R., Rahman, K., Devarapu, K., Narsina, D., Kamisetty, A., Gummadi, J. C. S., Talla, R. R., Onteddu, A. R., & Kothapalli, S. (2018). Predictive Analytics and Generative AI for Optimizing Cervical and Breast Cancer Outcomes: A Data-Centric Approach. *ABC Research Alert*, *6*(3), 214-223. https://doi.org/10.18034/ra.v6i3.672

Lorgelly, P. K., Doble, B., Knott, R. J. (2016). Realising the Value of Linked Data to Health Economic Analyses of Cancer Care: A Case Study of Cancer 2015. *PharmacoEconomics*, *34*(2), 139-154. https://doi.org/10.1007/s40273-015-0343-2

Lubelski, D., Alentado, V., Nowacki, A. S., Shriver, M., Abdullah, K. G. (2018). Preoperative Nomograms Predict Patient-Specific Cervical Spine Surgery Clinical and Quality of Life Outcomes. *Neurosurgery*, *83*(1), 104-113. https://doi.org/10.1093/neuros/nyx343

Marton, T. (2012). Program and Abstracts from the 2011 Joint Annual Meeting of the American Association for Cancer Education, the European Association for Cancer Education and the Cancer Patient Education Network--Buffalo, New York, Sept 8-10, 2011. *Journal of Cancer Education, suppl. Supplement*, *27*, 173-249. https://doi.org/10.1007/s13187-012-0381-9

Meng, Y., Sun, J., Qu, N., Zhang, G., Yu, T. (2019). Application of Radiomics for Personalized Treatment of Cancer Patients. *Cancer Management and Research*, *11*, 10851-10858. https://doi.org/10.2147/CMAR.S232473

Rodriguez, M., Mohammed, M. A., Mohammed, R., Pasam, P., Karanam, R. K., Vennapusa, S. C. R., & Boinapalli, N. R. (2019). Oracle EBS and Digital Transformation: Aligning Technology with Business Goals. *Technology & Management Review*, *4*, 49-63. https://upright.pub/index.php/tmr/article/view/151

Rodriguez, M., Sridharlakshmi, N. R. B., Boinapalli, N. R., Allam, A. R., & Devarapu, K. (2020). Applying Convolutional Neural Networks for IoT Image Recognition. *International Journal of Reciprocal Symmetry and Theoretical Physics*, *7*, 32-43. https://upright.pub/index.php/ijrstp/article/view/158

Shafqat, S., Abbasi, A., Khan, M. N. A., Qureshi, M. A., Amjad, T. (2018). Context Aware SmartHealth Cloud Platform for Medical Diagnostics. *International Journal of Advanced Computer Science and Applications*, *9*(7). https://doi.org/10.14569/IJACSA.2018.090741

Sridharlakshmi, N. R. B. (2020). The Impact of Machine Learning on Multilingual Communication and Translation Automation. *NEXG AI Review of America, 1*(1), 85-100.

Sridharlakshmi, N. R. B. (2021). Data Analytics for Energy-Efficient Code Refactoring in Large-Scale Distributed Systems. *Asia Pacific Journal of Energy and Environment*, *8*(2), 89-98. https://doi.org/10.18034/apjee.v8i2.771

Thompson, C. R., Sridharlakshmi, N. R. B., Mohammed, R., Boinapalli, N. R., Allam, A. R. (2022). Vehicle-to-Everything (V2X) Communication: Enabling Technologies and Applications in Automotive Electronics. *Asian Journal of Applied Science and Engineering, 11*(1), 85-98.

Thompson, C. R., Talla, R. R., Gummadi, J. C. S., Kamisetty, A (2019). Reinforcement Learning Techniques for Autonomous Robotics. *Asian Journal of Applied Science and Engineering*, *8*(1), 85-96. https://ajase.net/article/view/94

Venkata, S. S. M. G. N., Gade, P. K., Kommineni, H. P., Manikyala, A., & Boinapalli , N. R. (2022). Bridging UX and Robotics: Designing Intuitive Robotic Interfaces. *Digitalization & Sustainability Review*, *2*(1), 43-56. https://upright.pub/index.php/dsr/article/view/159

Zarakovitis, D., Tsoromokos, D., Tsaloukidis, N., Lazakidou, A. (2018). Mobile Application for Patients' Waiting Time Control and Management of Diagnostic Imaging Examinations. *International Journal of Reliable and Quality E – Healthcare*, *7*(4), 20-33. https://doi.org/10.4018/IJRQEH.2018100102

Zhang, W., Chien, J., Jeongsik, Y., Rui, K. (2017). Network-based Machine Learning and Graph Theory Algorithms for Precision Oncology. *NPJ Precision Oncology*, *1*(1). https://doi.org/10.1038/s41698-017-0029-7

--0--